Prometic Life Sciences Inc. (PLI-T) Stock Predictions - Stockchase
WATCH LIST
76
Prometic Life Sciences Inc. (PLI-T)

ON STOCKCHASE SINCE Apr 2007

Has a technology for filtering blood.

biotechnology/pharmaceutical

Prometic Life Sciences In...

PLI-T

40 watching          
Join the Discussion

Prometic Life Sciences Inc. (PLI-T) SAVE Apr, 19, 2019, 9:25 am

0.05 0 (0%)

About Prometic Life Sciences Inc. (PLI-T)

Prometic Life Sciences Inc. is a Canadian publicly traded biopharmaceutical company. Prometic products are used in the purification of biologics, drug development, proteomics and the removal of pathogens. More at Wikipedia

What the experts are saying about PLI-T



  • All
  • Filtered
Signal Opinion Expert
SELL
Technically, the new low at 8 cents does not offer anything meaningful. He would look at tax loss selling. Take the tax loss and move on.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Technically, the new low at 8 cents does not offer anything meaningful. He would look at tax loss selling. Take the tax loss and move on.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$0.065
Owned Owned
Unknown

SELL
He has followed this for a long time. It extracts protein from blood plasma and a drug that treats inflammation. They have added massive debt -- about $250 billion. He thinks there will be dramatic issues ahead and it will not end well for common shareholders.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He has followed this for a long time. It extracts protein from blood plasma and a drug that treats inflammation. They have added massive debt -- about $250 billion. He thinks there will be dramatic issues ahead and it will not end well for common shareholders.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.155
Owned Owned
No

DON'T BUY
The recent significant fall of 22% last week, would not be a signal to buy. He would stay away.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The recent significant fall of 22% last week, would not be a signal to buy. He would stay away.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jeff Parent B.

VP & Portf, Castlemoore Inc....

Price Price
$0.175
Owned Owned
No

WAIT
The big challenge is getting their product to market. They have most of the cash they need into 2020, which should buy them enought time. He is watching to see how revenues ramp up next year.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The big challenge is getting their product to market. They have most of the cash they need into 2020, which should buy them enought time. He is watching to see how revenues ramp up next year.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Campbell

President , Stone Castle Investm...

Price Price
$0.400
Owned Owned
No

SELL
He has been disappointed in the company but in clinical trials and the FDA process, things don't go as well as you want. They ran into a cash crush so they extended the terms of their debt. It is way down and the time-frame is extended. You should move on. There is tax loss selling.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He has been disappointed in the company but in clinical trials and the FDA process, things don't go as well as you want. They ran into a cash crush so they extended the terms of their debt. It is way down and the time-frame is extended. You should move on. There is tax loss selling.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$0.400
Owned Owned
No

DON'T BUY

The key is their ability to take a bag of plasma and extract a bunch of proteins.  They can sell as much as they can produce.  The market is concerned about their spending in R&D.  It appears to be a long way away from payday.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

The key is their ability to take a bag of plasma and extract a bunch of proteins.  They can sell as much as they can produce.  The market is concerned about their spending in R&D.  It appears to be a long way away from payday.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.460
Owned Owned
Unknown

DON'T BUY

They have patents on plasma protein drugs that are interesting. The company had significant success pushing these through the FDA stages but they recently ran into a delay and the stock dropped precipitously. He has been short for a while thinking the market cap was overvalued for the ultimate end market they were pursuing. Now that the stock has dropped so much, his short position is smaller. This is a highly speculative position. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They have patents on plasma protein drugs that are interesting. The company had significant success pushing these through the FDA stages but they recently ran into a delay and the stock dropped precipitously. He has been short for a while thinking the market cap was overvalued for the ultimate end market they were pursuing. Now that the stock has dropped so much, his short position is smaller. This is a highly speculative position. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
James Hodgins

Chief Inve, Curvature Hedge Stra...

Price Price
$0.750
Owned Owned
Unknown

SELL

He is short this company presently.  The market cap is quite high compared to his estimate of value.  The company appears to be quite promotional compared to others.  Their plasma protein product is easy to get through the FDA and subject to hype at each easy approval stage.  He does not see revenues and earnings to back it up. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He is short this company presently.  The market cap is quite high compared to his estimate of value.  The company appears to be quite promotional compared to others.  Their plasma protein product is easy to get through the FDA and subject to hype at each easy approval stage.  He does not see revenues and earnings to back it up. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
James Hodgins

Chief Inve, Curvature Hedge Stra...

Price Price
$1.350
Owned Owned
No

WATCH

He believes this has been very volatile due to an overhang and the potential need for more financing.  It is stabilizing now and they have received an investment from the Thompson family.  He thinks they should begin to receive approval soon with sales later this year.  They do not own it presently, although they have held it in the past. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He believes this has been very volatile due to an overhang and the potential need for more financing.  It is stabilizing now and they have received an investment from the Thompson family.  He thinks they should begin to receive approval soon with sales later this year.  They do not own it presently, although they have held it in the past. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Campbell

President , Stone Castle Investm...

Price Price
$1.460
Owned Owned
No

COMMENT

Prometic has two parts to its business. They can buy a bag of plasma for $200US and extract 11-13 high profile proteins. They have already applied to do 4 of those. There is an almost unlimited market for one of those, plasminogen, because there is no other supply of it. They’re also working on another drug that targets fibrosis. The studies for this drug are very costly, so PLI has had to raise a lot of capital. This will take a long time, is very risky, but will pay off well if successful. They are expected to break even next year based on their protein extraction.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Prometic has two parts to its business. They can buy a bag of plasma for $200US and extract 11-13 high profile proteins. They have already applied to do 4 of those. There is an almost unlimited market for one of those, plasminogen, because there is no other supply of it. They’re also working on another drug that targets fibrosis. The studies for this drug are very costly, so PLI has had to raise a lot of capital. This will take a long time, is very risky, but will pay off well if successful. They are expected to break even next year based on their protein extraction.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$1.590
Owned Owned
Unknown

COMMENT

The near to intermediate term is a bit of a challenge. They have technology to extract proteins from a bag of plasma. Their specialty is that they require a lot less CapX and operating costs to do it, and can end up getting much higher yields. The current process, which is over 40 years old, is maximized and optimized for something totally different in the proteins they were getting. They have approval to get plasminogen. Spending a ton of money to go through the formal drug testing process. It’s not expected to earn any money in 2018, but a loss of $.13 a share. Expected to break even in 2019.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

The near to intermediate term is a bit of a challenge. They have technology to extract proteins from a bag of plasma. Their specialty is that they require a lot less CapX and operating costs to do it, and can end up getting much higher yields. The current process, which is over 40 years old, is maximized and optimized for something totally different in the proteins they were getting. They have approval to get plasminogen. Spending a ton of money to go through the formal drug testing process. It’s not expected to earn any money in 2018, but a loss of $.13 a share. Expected to break even in 2019.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$1.680
Owned Owned
No

COMMENT

Doing interesting drug trials, with a near-term opportunity for their orphan drug Placminogen, a specialty protein. With Placminogen they can basically sell almost everything they can produce. Earnings estimates for 2019 is basically zero. You are buying this for 2 reasons. 1.) The manufacturing process; buying a bag of plasma for $120, breaking out a large number of proteins, and selling it over time for about $1000. 2.) their drug PBI4050 which is targeted towards fibrosis, where early results are quite positive. To develop a drug and go through phase 2 and 3 drug trials, is extremely expensive. If your time frame is 3 years, he thinks you will be happy. A speculative company working with some very interesting drug opportunities.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Doing interesting drug trials, with a near-term opportunity for their orphan drug Placminogen, a specialty protein. With Placminogen they can basically sell almost everything they can produce. Earnings estimates for 2019 is basically zero. You are buying this for 2 reasons. 1.) The manufacturing process; buying a bag of plasma for $120, breaking out a large number of proteins, and selling it over time for about $1000. 2.) their drug PBI4050 which is targeted towards fibrosis, where early results are quite positive. To develop a drug and go through phase 2 and 3 drug trials, is extremely expensive. If your time frame is 3 years, he thinks you will be happy. A speculative company working with some very interesting drug opportunities.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$1.550
Owned Owned
Yes

COMMENT

This does blood plasma protein. It is something that has been very easy for them to get FDA approval for their treatments. However, revenues and cash flow just haven’t come as they promised in the past. Did a pretty dilutive equity raise recently, which didn’t go that well. He is Short this, and probably will stay Short until the stock from the equity deal gets cleaned up.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This does blood plasma protein. It is something that has been very easy for them to get FDA approval for their treatments. However, revenues and cash flow just haven’t come as they promised in the past. Did a pretty dilutive equity raise recently, which didn’t go that well. He is Short this, and probably will stay Short until the stock from the equity deal gets cleaned up.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
James Hodgins

Chief Inve, Curvature Hedge Stra...

Price Price
$1.780
Owned Owned
Yes

HOLD

They are going to have a lot of catalysts between now and Q1 2018 on their drugs and some of their trials.  He sold it higher up for technical reasons.  He would hold onto it because of the catalysts.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They are going to have a lot of catalysts between now and Q1 2018 on their drugs and some of their trials.  He sold it higher up for technical reasons.  He would hold onto it because of the catalysts.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Campbell

President , Stone Castle Investm...

Price Price
$1.800
Owned Owned
No

COMMENT

There should be some news. They have some drug developments coming through the pipeline, and some of their partners are going to have some news. You might get more activity and more interest in the stock over the balance of the year. They’ve done a couple of non-diluted financings and loaded up the balance sheets quite nicely.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

There should be some news. They have some drug developments coming through the pipeline, and some of their partners are going to have some news. You might get more activity and more interest in the stock over the balance of the year. They’ve done a couple of non-diluted financings and loaded up the balance sheets quite nicely.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$2.030
Owned Owned
Unknown

Showing 1 to 15 of 76 entries
Successfully Saved Company
Successfully Saved Company